Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 9/20 | 0.38 |
| ▸ | HSD17B13 | Q7Z5P4 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477131 | 0.91 | PPARD (0.38) | KLKB1HSD17B13PPARGP2RX7 | |
| SCHEMBL6475756 | 0.90 | EPHX2 (0.39) | KLKB1HSD17B13PPARGCHRM4P2RX7 | |
| SCHEMBL6486745 | 0.84 | EPHX2 (0.35) | HSD17B13PPARGCHRM4P2RX7PDE4A | |
| SCHEMBL6482838 | 0.84 | EPHX2 (0.35) | HSD17B13PPARGCHRM4P2RX7PDE4A | |
| SCHEMBL6486884 | 0.83 | PDE4A (0.46) | HSD17B13CHRM4P2RX7PDE4APDE4B | |
| SCHEMBL6475255 | 0.83 | HPGD (0.40) | HSD17B13PPARGP2RX7 | |
| SCHEMBL6476446 | 0.82 | ALDH1A1 (0.34) | KLKB1HSD17B13P2RX7TP53 | |
| SCHEMBL6474731 | 0.79 | PDE4A (0.36) | HSD17B13CHRM4P2RX7PDE4APDE4B | |
| SCHEMBL7226091 | 0.76 | P2RX7 (0.39) | KLKB1GSK3BPPARGCHRM4P2RX7 | |
| SCHEMBL6475573 | 0.76 | PDE4A (0.36) | KLKB1GSK3BPPARGP2RX7EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355907-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-10-02 | — | — | US | claimed |
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-07-10 | — | — | US | claimed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | claimed |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002060898-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-6894041-B2 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-05-17 | — | — | US | disclosed |
| US-6869945-B2 | Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, NOX1, NOX3 | KLKB1 4118/4885HSD17B13 279/4885GSK3B 2334/4885 |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, PDE4A | KLKB1 3019/4885HSD17B13 335/4885GSK3B 3194/4885 |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE3B | KLKB1 4032/4885HSD17B13 497/4885GSK3B 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.